The most recent report indicates that there are currently more than one thousand chikungunya cases in Suriname. But sources from within the healthcare sector claim that the number is most likely much higher. Suriname currently has more confirmed chikungunya cases than neighboring Guyana and French Guiana. French Guiana currently has 9 confirmed cases. Shortly after the first cases were reported, health officials have the order for fumigations to commence in residential areas. Neighboring Guyana still has not announced an official statement regarding to the number of chikungunya cases.

In 2014 Suriname was hit by the first wave of chikungunya cases. Back then more than 700 confirmed cases and 1 death were reported. Marowijneproject, Blauwgrond, Geyersvlijt, Clevia, Tamansari and Richelieu have been labeled as risk areas. The Pan American Health Organization (PAHO) has issued an epidemiological alert following a sustained increase in chikungunya cases in several countries in the Americas since late 2025 and into early 2026. The alert also highlights the re-emergence of local transmission in areas that had not reported virus circulation in several years. PAHO recommends that countries strengthen epidemiological and laboratory surveillance to detect cases and outbreaks early, ensure proper clinical management–especially for vulnerable groups such as pregnant women, children under 1 year of age, older adults, and people with underlying health conditions—and intensify integrated vector management actions, including the elimination of mosquito breeding sites. Chikungunya is a virus transmitted by Aedes aegypti and potentially Aedes albopictus mosquitoes, which also spread dengue, Zika, and other arboviruses. Infection can cause high fever and severe joint pain, often debilitating, along with muscle pain, headache, fatigue, nausea, and rash. Other, non-articular symptoms can range from mild to severe, with higher risk in children under 1-year, older adults, people with underlying health conditions, and pregnant women.

Chikungunya can also cause chronic joint pain, which may last from weeks to several months in about 60% of cases. There is no specific antiviral treatment; acute symptoms are managed with analgesics and antipyretics. High-risk patients should be assessed by health professionals for potential hospitalization and monitoring to prevent severe complications and fatalities.